ArticleBioinformation2026
Impact of zinc deficiency on the recurrence in aphthous stomatitis: A prospective case-control study.
Article in Bioinformation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent aphthous stomatitis (RAS) is one of the frequent problems of the mouth that affects 10 to 20 percent of the population. Therefore, it is of interest to find out if the level of zinc in the blood is related to the recurrence of RAS and if taking zinc can reduce the recurrence and severity of RAS. We enrolled 30 RAS patients with minor recurrent aphthous stomatitis, and 30 healthy controls matched to the RAS patients by age and sex from the clinic over 12 months and RAS patients had significantly lower fasting serum zinc levels than the controls (76.4 ± 11.2 µg/dL vs. 87.3 ±8.9 µg/dL; p < 0.001). Zinc deficiency was seen in 56.7 percent of RAS patients with serum zinc levels less than 70 µg/dL compared with 16.7 percent of the controls (p < 0.001). Thus, low serum levels of zinc are significant predictors of recurrence of RAS and zinc can be used as an additional preventive measure against RAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.